Nelfinavir: Difference between revisions

Jump to navigation Jump to search
Line 24: Line 24:
'''| [[Nelfinavir drug interactions|Drug Interactions]]'''
'''| [[Nelfinavir drug interactions|Drug Interactions]]'''
'''| [[Nelfinavir overdosage|Overdosage]]'''
'''| [[Nelfinavir overdosage|Overdosage]]'''
'''| [[Nelfinavir clinical studies|Clinical Studies]]'''
'''| [[Nelfinavir dosage and administration|Dosage and Administration]]'''
'''| [[Nelfinavir dosage and administration|Dosage and Administration]]'''
'''| [[Nelfinavir how supplied|How Supplied]]'''
'''| [[Nelfinavir how supplied|How Supplied]]'''

Revision as of 16:45, 9 January 2014

Nelfinavir
VIRACEPT® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Overdosage
Dosage and Administration
How Supplied
Labels and Packages

For patient information, click here.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Category

Protease inhibitor

US Brand Names

VIRACEPT®

FDA Package Insert

Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Overdosage | Dosage and Administration | How Supplied | Labels and Packages

Mechanism of Action

Nelfinavir is an inhibitor of the HIV-1 protease. Inhibition of the viral protease prevents cleavage of the gag and gag-pol polyprotein resulting in the production of immature, non-infectious virus.[1]

References

  1. "VIRACEPT (NELFINAVIR MESYLATE) TABLET, FILM COATED VIRACEPT (NELFINAVIR MESYLATE) POWDER [AGOURON PHARMACEUTICALS INC]". Text " accessdate" ignored (help)